Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

In the early 1990s two isoforms of Cyclooxygenase (COX) were found: COX-1 and COX-2. It was suggested that the anti-inflammatory properties of non-steroidal anti-inflammatory drugs (NSAIDs) were related to a COX-2 inhibition, whereas their adverse effects occurred because of a COX-1 inhibition. This led to a massive era of pharmaceutical development, which has resulted in the introduction of a group of new NSAIDs: the COX-2 inhibitors. Due to an aggressive marketing, two of them, rofecoxib and celecoxib, are increasingly used for a variety of painful conditions. However, the view that COX-2 inhibitors are safer than conventional NSAIDs is likely to be flowed. Currently there is no evidence suggesting that the modestly COX-2 selective drug celecoxib is safer than conventional NSAIDs for the gastrointestinal tract, while there is considerable evidence that the highly COX-2 selective drug rofecoxib has increased cardiovascular toxicity compared with traditional NSAIDs. Currently, there is no rationale for the use of COX-2 inhibitors. Rather, simple analgesics (paracetamol) and, if necessary, traditional NSAIDs (mainly didofenac or naproxen) should be used, potentially combined with a proton-pump inhibitor (e.g. omeprazole).


Journal article


Zeitschrift fur Allgemeinmedizin

Publication Date





288 - 293